Fast disintegrating compositions of meloxicam
View Patent ↗The invention provides pharmaceutical compositions comprising a therapeutically effective amount of meloxicam, or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical compositions are in the form of a fast disintegrating dosage form suitable for releasing meloxicam rapidly in the oral cavity. Also provided are processes for preparing a pharmaceutical composition of the invention. Further provided are methods of treating arthritis or pain in a subject in need thereof, the method comprising orally administering to the subject a therapeutically effective amount of a pharmaceutical composition according to the invention.
1. A pharmaceutical composition in a dosage form comprising a therapeutically effective amount of meloxicam, or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical composition is in the form of a fast disintegrating dosage form suitable for releasing meloxicam rapidly in the oral cavity and the particle size (D90) of meloxicam is in the range of about 5 to 40 microns.
2. The composition of claim 1 , wherein meloxicam is released in less than about 30 seconds in the oral cavity.
3. The composition of claim 1 , wherein meloxicam is released in less than about 10 seconds in the oral cavity.
4. The composition of claim 1 , wherein meloxicam is released in less than about 3 seconds in the oral cavity.
5. The composition of claim 1 , wherein meloxicam is selected from the group consisting of crystalline phase, an amorphous phase, a semi-crystalline phase, a semi-amorphous phase, and a combination thereof.
6. The composition of claim 1 , wherein the amount of meloxicam is added in the range of about 5 mg to 20 mg.
7. The composition of claim 1 , wherein the amount of meloxicam is in the range of about 20% to 45% by weight of the pharmaceutical composition.
8. The composition of claim 1 , further comprising a matrix network.
9. The composition of claim 8 , wherein the matrix network comprises at least one matrix former selected from gelatin, hydrolyzed dextran, and alginate.
10. The composition of claim 8 , wherein the matrix former is a combination of gelatin and mannitol.
11. The composition of claim 10 , wherein the amount of gelatin is in the range of about 15% to 40% by weight of the pharmaceutical composition.
12. The composition of claim 10 , wherein the amount of gelatin is in the range of about 28% to 33% by weight of the pharmaceutical composition.
13. The composition of claim 10 , wherein the amount of mannitol is in the range of about 10% to 30% by weight of the pharmaceutical composition.
14. The composition of claim 10 , wherein the amount of mannitol is in the range of about 20% to 25% by weight of the pharmaceutical composition.
15. The composition of claim 8 , wherein the matrix network is obtained by freeze drying a mixture of a therapeutically effective amount of meloxicam, a dispersing agent, and a matrix former to a solid state.
16. The composition of claim 8 , further comprising at least one excipient selected from a pH modifier, sweetener and flavor.
17. The composition of claim 16 , wherein the pH modifier is citric acid.
18. The composition of claim 16 , wherein the sweetener is aspartame.
19. The composition of claim 16 , further comprising a taste masking agent and/or a coloring agent.
20. The composition of claim 1 packaged in a blister pocket.
21. The composition of claim 1 , wherein the particle size (D90) of meloxicam is in the range of about 15 to 30 microns.
22. The composition of claim 1 , wherein the particle size (D90) of meloxicam is in the range of about 18 to 21 microns.
23. The composition of claim 1 , wherein the particle size (D90) of meloxicam is in the range of about 5 to 10 microns.
24. The composition of claim 1 , wherein the particle size (D90) of meloxicam is about 6 microns.